Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B₂

References

• Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005;32:2218-24
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Biskupiak JE, Brixner DI, Howard KB, et al. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 2006;20:7-14
   PubMedGoogle Scholar
• Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Science Paper. Concomitant use of ibuprofen and aspirin: potential for attenuation of the antiplatelet effect of aspirin. September 8, 2006. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf [Last accessed 11 January 2010]
   Google Scholar
• Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SV, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001;345:1809-17
   PubMed Web of Science ®Google Scholar
• Ouellet M, Percival MD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophysics 2001;387:273-80
   PubMed Web of Science ®Google Scholar
• Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383-90
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058-73
   PubMed Web of Science ®Google Scholar
• Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005;27:185-91
   PubMed Web of Science ®Google Scholar
• Alessandrini P, Avagaro P, Bittolo BG, et al. Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8
   PubMed Web of Science ®Google Scholar
• Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 1999;84:404-9
   PubMed Web of Science ®Google Scholar
• Brown N, May JA, Wilcox RG, et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 1999;48:57-62
   PubMed Web of Science ®Google Scholar
• Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-6
   PubMed Web of Science ®Google Scholar
• Awtry E, Loscalzo J. Aspirin. Circulation 2000;101:1206-18
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83
   PubMed Web of Science ®Google Scholar
• Schiff M, Hochberg MC, Oldenhof J, et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 2009;25:2471-7
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-71
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322:453-60
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20
   PubMed Web of Science ®Google Scholar
• Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-46
   PubMed Web of Science ®Google Scholar
• FDA Advisory Committee Background Information, presented to Arthritis Advisory Committee, February 8, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf [Last accessed 11 January 2010]
   Google Scholar
• Galliard-Grigioni KS, Reinhart WH. A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 2009;609:96-9
   PubMed Web of Science ®Google Scholar
• Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008;101:1060-3
   PubMed Web of Science ®Google Scholar
• Haubelt H, Anders C, Vogt A, et al. Variables influencing Platelet Function Analyzer-100™ closure times in healthy individuals. Br J Haematol 2005;130:759-67
   PubMed Web of Science ®Google Scholar
• Von Lewinski F, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis. J Stroke Cerebrovasc Dis 2009;18:111-15
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Wei L. Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?. Basic Clin Pharmacol Toxicol 2006;98:275-80
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with lumiracoxib, ibuprofen, or naproxen. Ann Rheum Dis 2007;66:764-70
   PubMed Web of Science ®Google Scholar